Results from Phase 1 Trial of IPI-504,a Novel HSP90 Inhibitor,in Tyrosine Kinase Inhibitor -Resistant GIST and other arcomas
Safety,pharmacokinetics and preliminary activity of the anti-IGFR-IR antibody CP-751,871 in patients with sarcoma
声明：
1.丁香会议频道仅负责发布会议信息，如需参会、获取邀请函或会议日程，请与主办单位联系
2.部分会议信息来自互联网，如您发现信息有误，请联系meeting@dxy.cn纠错
3.如您发现信息不全，可点击Google搜索更多
4.更多服务信息请点击这里
